GSK press releases Follow Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES) Positive data from a pivotal study supports new regulatory filing in HES https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-is-the-first-treatment-to-show-a-significant-reduction-in-flares-for-patients-with-hypereosinophilic-syndrome-hes/ gsk.com
